Search results for: Jun Ho Yi

Items from 1 to 12 out of 12 results

article

Ruxolitinib shows activity against Hodgkin lymphoma but not primary mediastinal large B-cell lymphoma

Seok Jin Kim, Dok Hyun Yoon, Hye Jin Kang, Jung Yong Hong, more

BMC Cancer > 2019 > 19 > 1 > 1-7

Background The upregulated expression of the JAK/STAT pathway promotes tumor growth in Hodgkin lymphoma (HL) and primary mediastinal large B-cell lymphoma (PMBCL). Based on the hypothesis that JAK2 is a therapeutic target, we performed a prospective pilot study using ruxolitinib. Methods Relapsed or refractory patients with HL or PMBCL were eligible for this study, and JAK2 amplification was assessed...

article

Multicenter retrospective analysis of the clinicopathologic features of monomorphic epitheliotropic intestinal T-cell lymphoma

Jun Ho Yi, Gyeong-Won Lee, Young Rok Do, Hye Ra Jung, more

Annals of Hematology > 2019 > 98 > 11 > 2541-2550

Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) is a provisional entity in the 2017 World Health Organization classifications. To further elucidate the clinicopathologic features of this new disease, we carried out a retrospective, multicenter analysis of 42 patients with MEITL. The median age of the patients was 59 years (range, 20–84 years), and 27 patients (64 %) were male. Thirty-two...

article

Intrinsic resistance to sunitinib in patients with metastatic renal cell carcinoma

Sung Hee Lim, In Gyu Hwang, Jun Ho Ji, Sung Yong Oh, more

Asia‐Pacific Journal of Clinical Oncology > 13 > 1 > 61 - 67

Aim Although targeting angiogenesis with vascular endothelial growth factor receptor (VEGFR) inhibitors has demonstrated efficacy in the treatment of renal cell carcinoma, primary, intrinsic resistance to the VEGFR inhibitor sunitinib is not fully understood in a subset of metastatic RCC (mRCC) patients. Methods Between 2008 and 2012, a total of 134 patients with mRCC were treated with first‐line...

chapter

A Construction of the Adapted Ontology Server in EC

Hanhyuk Chung, Joong-min Choi, Jun-ho Yi, Junghyun Han, more

Lecture Notes in Computer Science > Intelligent Data Engineering and Automated Learning — IDEAL 2000. Data Mining, Financial Engineering, and Intelligent Agents > Internet Applications > 355-360

Ontology is an essential element for the agent system. The agent can share its knowledge and communicate with each other with it. As the agent system is more widely applied, the importance of ontology is increasing. Though there were some approaches to construct ontology, it was too far to satisfy practical needs. In this paper we have constructed an Ontology Server, which provides ontology adapted...

article

Anti-tumoral effect of arsenic compound, sodium metaarsenite (KML001), in non-Hodgkin’s lymphoma: an in vitro and in vivo study

Jin Sun Yoon, Deok Won Hwang, Eun Shil Kim, Jung Soon Kim, more

Investigational New Drugs > 2016 > 34 > 1 > 1-14

Summary Arsenic compounds have been used in traditional medicine for several centuries. KML001 (sodium metaarsenite; NaAsO₂) is an orally bio-available arsenic compound with potential anti-cancer activity. However, the effect of KML001 has not been studied in lymphoid neoplasms. The aim of this study is to evaluate the anti-proliferative effect of KML001 in non-Hodgkin’s lymphoma and to compare its...

article

Genome-wide single-nucleotide polymorphism array-based karyotyping in myelodysplastic syndrome and chronic myelomonocytic leukemia and its impact on treatment outcomes following decitabine treatment

Jun Ho Yi, Jungwon Huh, Hee-Jin Kim, Sun-Hee Kim, more

Annals of Hematology > 2013 > 92 > 4 > 459-469

Decitabine is a hypomethylating agent with proven clinical efficacy in myelodysplastic syndrome (MDS). The current study analyzed the role of single nucleotide polymorphism array (SNP-A)-based karyotyping in prediction of clinical outcome in MDS or chronic myelomonocytic leukemia (CMML) patients following decitabine therapy. A total of 61 MDS/CMML patients treated with decitabine were evaluated with...

article

A phase II study of sunitinib as a second-line treatment in advanced biliary tract carcinoma: A multicentre, multinational study

Jun Ho Yi, Sumitra Thongprasert, Jeeyun Lee, D.C. Doval, more

European Journal of Cancer > 2012 > 48 > 2 > 196-201

Biliary tract carcinoma (BTC) is rare in the West, but not uncommon in Asia and is a highly fatal malignancy. VEGF expression is related with poor outcome in patients with BTC. Therefore, we conducted a phase II study to evaluate the efficacy and safety of sunitinib as second-line treatment.This was a prospective, single-arm, multicentre, multinational study. Patients with unresectable, metastatic...

article

Clinical presentation of carcinoma of unknown primary: 14 years of experience

Jun Ho Yi, Yoon Choi, Su Jin Lee, Hee Kyung Ahn, more

Tumor Biology > 2011 > 32 > 1 > 45-51

A carcinoma of unknown primary (CUP) is a histologically confirmed metastatic cancer without a definitive primary site after performing a detailed medical examination. The purpose of the study was to classify unfavorable CUPs into more reliable disease entities, which reflect the clinical course. We reviewed the medical records of patients diagnosed with a CUP between January 1995 and March 2008....

article

Accuracy of RECIST 1.1 for non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors

Jong-Mu Sun, Myung-Ju Ahn, Min Jae Park, Jun Ho Yi, more

Lung Cancer > 2010 > 69 > 1 > 105-109

The Response Evaluation Criteria in Solid Tumors (RECIST) has been revised (RECIST 1.1) since initial publication of RECIST 1.0 in 2000. Major changes in RECIST 1.1 involve lymph node measurement, the maximum number of target lesions, and the definition of disease progression (PD). The purpose of this study was to evaluate the accuracy of RECIST 1.1 for non-small cell lung cancer (NSCLC) patients...

article

¹⁸F‐FDG uptake and its clinical relevance in primary gastric lymphoma

Jun Ho Yi, Seok Jin Kim, Joon Young Choi, Young Hyeh Ko, more

Hematological Oncology > 28 > 2 > 57 - 61

We studied the clinical relevance of ¹⁸F‐fluorodeoxyglucose (¹⁸F‐FDG) uptake in patients with primary gastric lymphoma underwent positron emission tomography (PET)/ computed tomography (CT) scan. Forty‐two patients with primary gastric lymphoma were analysed: 32 diffuse large B‐cell lymphomas (DLBCL) and 10 extranodal marginal zone B‐cell lymphomas of mucosa‐associated lymphoid tissue (MALT lymphomas)...

article

Improved treatment outcome of primary mediastinal large B-cell lymphoma after introduction of rituximab in Korean patients

Hee Kyung Ahn, Seok Jin Kim, Jina Yun, Jun Ho Yi, more

International Journal of Hematology > 2010 > 91 > 3 > 456-463

The addition of rituximab to cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) improved the outcome of patients with diffuse large B-cell lymphoma (DLBCL). However, the impact of rituximab (R-CHOP) is still not determined in primary mediastinal large B-cell lymphoma (PMBCL), a subtype of DLBCL, especially in Asian patients. Thus, we analyzed the treatment outcome of PMBCL patients (...

article

Rituximab-induced acute thrombocytopenia: a case report and review of the literature

Jun Ho Yi, Seok Jin Kim, Hee Kyung Ahn, Su Jin Lee, more

Medical Oncology > 2009 > 26 > 1 > 45-48

Rituximab is a chimeric monoclonal antibody directed against the phosphoprotein CD20. Because of its efficacy and acceptable toxicity profile, rituximab is now commonly used for the treatment of CD20-positive B-cell malignancies, including B-cell non-Hodgkin’s lymphoma. However, rituximab-induced acute thrombocytopenia is an extremely rare side effect. We report a case of acute thrombocytopenia occurring...

Filter options

Publication date

Set your own date range

INFONA - science communication portal

Search results for: Jun Ho Yi

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Publication type

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options